Consumer group challenges Gilead patents on hepatitis C drug

Media Article 25 Oct 2017

The New York City-based Initiative for Medicines, Access & Knowledge (I-MAK) asked the PTO’s Patent Trial and Appeal Board to invalidate six Gilead patents covering Sovaldi’s active ingredient and structure, saying they describe obvious tweaks to existing compounds used in older HIV and cancer drugs.

Partner with us now to build
a more just and equitable
medicine system for all.